Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome
OBJECTIVE: Statins are recommended as the first-line treatments for reducing the risk of major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS). The present study aimed to establish the baseline lipid levels associated with the greatest benefit from statin therapy in this population.
METHODS: The study used a retrospective cohort methodology. In total, 636 patients with ACS were enrolled at Shaanxi Provincial People's Hospital from 2011 to 2013. Participants were divided into four groups (group 1, hyperlipidemia with inconsistent statin use; group 2, no hyperlipidemia with inconsistent statin use; group 3, no hyperlipidemia with consistent statin use; and group 4, hyperlipidemia with consistent statin use).
RESULTS: Patients in groups 3 (hazard ratio [HR] = 0.49, 95% confidence interval [CI] = 0.29-0.82) and 4 (HR = 0.21, 95% CI = 0.10-0.45) had lower risks of MACE than those in group 1. In subgroup analysis, patients in group 4 had a lower risk of MACE than those in group 3 (adjusted HR = 0.43, 95% CI = 0.21-0.89).
CONCLUSION: Sustained statin therapy is associated with a lower risk of adverse outcomes in patients with ACS, especially in those with higher baseline lipid levels.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
---|---|
Enthalten in: |
The Journal of international medical research - 48(2020), 11 vom: 02. Nov., Seite 300060520965848 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhu, Ling [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acute coronary syndrome |
---|
Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.1177/0300060520965848 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317069934 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317069934 | ||
003 | DE-627 | ||
005 | 20231225162446.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1177/0300060520965848 |2 doi | |
028 | 5 | 2 | |a pubmed24n1056.xml |
035 | |a (DE-627)NLM317069934 | ||
035 | |a (NLM)33138662 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhu, Ling |e verfasserin |4 aut | |
245 | 1 | 0 | |a Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2021 | ||
500 | |a Date Revised 14.05.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: Statins are recommended as the first-line treatments for reducing the risk of major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS). The present study aimed to establish the baseline lipid levels associated with the greatest benefit from statin therapy in this population | ||
520 | |a METHODS: The study used a retrospective cohort methodology. In total, 636 patients with ACS were enrolled at Shaanxi Provincial People's Hospital from 2011 to 2013. Participants were divided into four groups (group 1, hyperlipidemia with inconsistent statin use; group 2, no hyperlipidemia with inconsistent statin use; group 3, no hyperlipidemia with consistent statin use; and group 4, hyperlipidemia with consistent statin use) | ||
520 | |a RESULTS: Patients in groups 3 (hazard ratio [HR] = 0.49, 95% confidence interval [CI] = 0.29-0.82) and 4 (HR = 0.21, 95% CI = 0.10-0.45) had lower risks of MACE than those in group 1. In subgroup analysis, patients in group 4 had a lower risk of MACE than those in group 3 (adjusted HR = 0.43, 95% CI = 0.21-0.89) | ||
520 | |a CONCLUSION: Sustained statin therapy is associated with a lower risk of adverse outcomes in patients with ACS, especially in those with higher baseline lipid levels | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Chinese | |
650 | 4 | |a Lipid | |
650 | 4 | |a acute coronary syndrome | |
650 | 4 | |a cohort study | |
650 | 4 | |a hyperlipidemia | |
650 | 4 | |a major adverse cardiovascular events | |
650 | 4 | |a statin | |
650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
650 | 7 | |a Lipids |2 NLM | |
700 | 1 | |a Liu, Ying |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zhu |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Liqin |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Hong |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yong |e verfasserin |4 aut | |
700 | 1 | |a Liu, Fuqiang |e verfasserin |4 aut | |
700 | 1 | |a Liu, Peng |e verfasserin |4 aut | |
700 | 1 | |a Liu, Zhongwei |e verfasserin |4 aut | |
700 | 1 | |a Wang, Junkui |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of international medical research |d 1973 |g 48(2020), 11 vom: 02. Nov., Seite 300060520965848 |w (DE-627)NLM000148504 |x 1473-2300 |7 nnns |
773 | 1 | 8 | |g volume:48 |g year:2020 |g number:11 |g day:02 |g month:11 |g pages:300060520965848 |
856 | 4 | 0 | |u http://dx.doi.org/10.1177/0300060520965848 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 48 |j 2020 |e 11 |b 02 |c 11 |h 300060520965848 |